A Comparative Study of the Effectiveness of Warfarin and Rivaroxaban in patients with cerebrovascular thrombosis

A Comparative Study of the Effectiveness of Warfarin and Rivaroxaban in patients with cerebrovascular thrombosis (CVT)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130812014333N188

Enrollment

Registered

2022-08-06

Start date

2022-08-06

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral infarction. Cerebral infarction

Interventions

Intervention 1: In the first intervention group, warfarin 5-10 mg or 2-5 mg is prescribed once a day according to the patient's condition. The adjustment of subsequent doses is based on the INR answer

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Informed consent Patients with final diagnosis of cerebrovascular thrombosis Not receiving warfarin and rivaroxaban drugs in the previous 6 months

Exclusion criteria

Exclusion criteria: Patients with severe bleeding Heart disorders Renal failure with creatinine clearance less than 30 ml/min Patients with a history of antiphospholipid (APS)

Design outcomes

Primary

Measure	Time frame
Hospitalization period. Timepoint: Upon arrival, 3 months and 6 months after the start of treatment. Method of measurement: patient file.;Bleeding. Timepoint: Upon arrival, 3 months and 6 months after the start of treatment. Method of measurement: Ask the patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaber Yarali

Kermanshah University of Medical Sciences

saberyarali67@gmail.com+98 83 3427 6306

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026